Neurocrine(US:NBIX)2025-10-28 20:02Financial Performance - Total net product sales for Q3 2025 were $790 million, reflecting a 28% year-over-year growth[5] - INGREZZA net product sales for Q3 2025 were $687 million, representing a 12% year-over-year growth[5] - CRENESSITY net product sales for Q3 2025 were $98 million, with 540 total new patient enrollment start forms[5] - GAAP net income for Q3 2025 was $209.5 million, compared to $129.8 million in Q3 2024, marking a 62% increase[10] - Non-GAAP net income for Q3 2025 was $222.1 million, up from $189.2 million in Q3 2024, reflecting a 17% increase[10] - Net product sales for Q3 2025 reached $789.9 million, a 28.1% increase from $616.6 million in Q3 2024[20] - Total revenues for the nine months ended September 30, 2025, were $2,055.0 million, up 19.0% from $1,727.6 million in the same period of 2024[20] - Operating income for Q3 2025 was $239.0 million, a 30.0% increase from $183.8 million in Q3 2024[20] - Net income for Q3 2025 was $209.5 million, up 61.5% from $129.8 million in Q3 2024[20] - Diluted earnings per share for Q3 2025 were $2.04, compared to $1.24 in Q3 2024, representing a 64.5% increase[20] - Non-GAAP net income for Q3 2025 was $222.1 million, compared to $189.2 million in Q3 2024, reflecting a 17.4% increase[24] Cash and Assets - Total cash, cash equivalents, and marketable securities as of September 30, 2025, were approximately $2.1 billion[10] - Cash, cash equivalents, and marketable securities totaled $1,114.8 million as of September 30, 2025, an increase from $1,076.1 million at the end of 2024[22] - Total assets increased to $4,265.7 million as of September 30, 2025, compared to $3,718.7 million at the end of 2024[22] - Stockholders' equity rose to $3,003.6 million as of September 30, 2025, up from $2,589.7 million at the end of 2024[22] Research and Development - The company initiated a second Phase 3 registrational clinical trial for direclidine as a potential treatment for schizophrenia[5] - Research and development expenses for Q3 2025 were $250.0 million, compared to $195.0 million in Q3 2024, reflecting a 28.2% increase[20] Sales and Marketing Strategy - The company plans to expand the INGREZZA and CRENESSITY sales teams by the end of Q1 2026 to maximize commercial momentum[8] Awards and Recognition - The company was honored with the 2025 Poster Award at the 38th annual Psych Congress for new data presented from the Phase 2 SAVITRI™ study[5] Guidance - Full year 2025 guidance for INGREZZA net product sales is expected to be between $2.5 billion and $2.55 billion[11]